Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.6% vs industry average

Late-Stage Pipeline

100%

3 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3
3(100.0%)
3Total
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06549686Phase 3Recruiting

A Phase III Study of CLS2901C in Patients With Osteoarthritis of the Knee

Role: lead

NCT04689594Phase 3Terminated

A Study to Evaluate the Esophageal Stenosis Inhibition Effects of CLS2702C/CLS2702D After Endoscopic Submucosal Dissection (ESD) in Patients With Superficial Esophageal Cancer in the Steroid Administration Risk Group

Role: lead

NCT02866019Phase 3Completed

Human (Autologous) Oral Mucosal Cell Sheet Transplantation After ESD in Patients With Superficial Esophageal Cancer

Role: lead

All 3 trials loaded